drugset

drugset / Trial / NCT04772547

VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa

NCT04772547 ↗

Phase 2 Completed 6 enrolled University of Florida American Heart Association · collab Thomas Jefferson University · collab Yale University · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a pilot trial of a single loading dose of vigabatrin in post-anoxic status epilepticus.

Timeline

Start: 2021-09-22
Primary completion: 2023-06-07
Completion: 2024-01-23

Publications

Maciel CB, Teixeira FJP, Dickinson KJ, Spana JC, Merck LH, Rabinstein AA, Sergott R, Shan G, Miao G, Peloquin CA, Busl KM, Hirsch LJ. Early vigabatrin augmenting GABA-ergic pathways in post-anoxic status epilepticus (VIGAB-STAT) phase IIa clinical trial study protocol. Neurol Res Pract. 2022 Jan 24;4(1):4. doi: 10.1186/s42466-022-00168-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vigabatrin	Small molecule	4500 mg	Other

Indications